Table 2.
Patient characteristics by manufacturer group.
| Characteristics | MG 1 (n = 66) | MG 2 (n = 69) | P-Value |
|---|---|---|---|
| Age (years) | 65.1 ± 11.3 | 63.0 ± 10.9 | .28 |
| Male | 44 (66.7%) | 44.0 (63.8%) | .86 |
| Weight (kg) | 75.9 ± 15.5 | 80.6 ± 23.5 | .17 |
| Body mass index (kg/m2) | 27.0 ± 5.3 | 29.2 ± 7.4 | .05 |
| Body mass index group | .31 | ||
| <18.5 kg/m2 | 3 (4.5%) | 1 (1.4%) | |
| 18.5–24.9 kg/m2 | 22 (33.3%) | 22 (31.9%) | |
| 25–29.9 kg/m2 | 23 (34.8%) | 20 (29.0%) | |
| 30–34.9 kg/m2 | 14 (21.2%) | 14 (20.3%) | |
| 35–39.9 kg/m2 | 3 (4.5%) | 5 (7.2%) | |
| ≥40 kg/m2 | 1 (1.5%) | 7 (10.1%) | |
| Race | .69 | ||
| Black or African American | 21 (31.8%) | 28 (40.6%) | |
| White | 7 (10.6%) | 7 (10.1%) | |
| Asian | 6 (9.1%) | 7 (10.1%) | |
| American Indian or Alaska Native | 1 (1.5%) | 0 (0.0%) | |
| Native Hawaiian or other Pacific Islander | 0 (0.0%) | 1 (1.4%) | |
| Unknown | 31 (47.0%) | 26 (37.7%) | |
| Ethnicity | .80 | ||
| Non-Hispanic | 38 (57.6%) | 44 (63.8%) | |
| Hispanic | 25 (37.9%) | 22 (31.9%) | |
| Unknown | 3 (4.5%) | 3 (4.3%) | |
| History of diabetes | 35 (53.0%) | 38 (55.1%) | .95 |
| LHC indication | .58 | ||
| Acute coronary syndrome | 59 (89.4%) | 61 (88.4%) | |
| Stable ischemic heart disease | 6 (9.1%) | 6 (8.7%) | |
| VT/PVC etiology | 1 (1.5%) | 0 (0.0%) | |
| Staged PCI | 0 (0.0%) | 0 (0.0%) | |
| No LHC | 0 (0.0%) | 2 (2.9%) | |
| Intervention | .02 | ||
| Stent | 65 (98.5%) | 59 (85.5%) | |
| Number of stents (n) | 1.0 (1.0–2.0) | 2.0 (1.0–2.0) | |
| Medical management | 0 (0.0%) | 5 (7.2%) | |
| Other | 1 (1.5%) | 5 (7.2%) | |
| Clopidogrel responder | 23 (34.8%) | 38 (55.1%) | .03 |
| Adenosine diphosphate (%) | 46.5 (27.3–56.0) | 39.0 (25.0–55.0) | .24 |
| Adenosine diphosphate group | .02 | ||
| ≤40% | 23 (34.8%) | 38 (55.1%) | |
| 40%−50% | 12 (18.2%) | 4 (5.8%) | |
| >50% | 31 (47.0%) | 27 (39.1%) | |
| Arachidonic acid (%) | 16.5 (10.0–28.8) | 14.0 (7.0–27.0) | .30 |
| Arachidonic acid ≤20% | 38 (57.6%) | 44 (63.8%) | .58 |
| Time from clopidogrel load to lab measurement (hours) | 25.5 (19.2–64.2) | 23.4 (17.0–48.3) | .23 |
| Time from clopidogrel load to lab measurement by group | .63 | ||
| <24 hours | 30 (47.6%) | 36 (55.4%) | |
| 24–48 hours | 12 (19.0%) | 12 (18.5%) | |
| >48 hours | 21 (33.3%) | 17 (26.2%) | |
| Clopidogrel load strength | .84 | ||
| 300 mg | 24 (36.4%) | 22 (31.9%) | |
| 600 mg | 39 (59.1%) | 43 (62.3%) | |
| No load | 3 (4.5%) | 4 (5.8%) | |
| Targeted temperature management when loaded | 2 (3.0%) | 0 (0.0%) | .24 |
Data presented as mean ± standard deviation, median (interquartile range), or number (%).
ADP = adenosine diphosphate; LHC = left heart catheterization; PCI = percutaneous coronary intervention; MG = manufacturer group.